PREVAIL: PREvention of VTE After Acute Ischemic Stroke With LMWH Enoxaparin ( - VTE: Venous Thromboembolism - LMWH: Low Molecular Weight Heparin)


Phase 4 Results


There were fewer composite endpoints (DVT, PE) in patients treated with enoxaparin than with unfractionated heparin (UFH) during the 90-day treatment period (10.2% vs 18.1%; p=.0001; relative risk reduction 43%). Proximal DVT was also reduced (4.5% vs 9.6%; p=.0003; relative risk reduction 53%). Clinically important bleeding was not significantly different between enoxaparin and UFH (1.3% vs 0.7%, p=.20).